{"analyses":[{"ciLowerLimit":"1.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.46","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0005","paramType":"Odds Ratio (OR)","paramValue":"3.61","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.83","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0019","paramType":"Odds Ratio (OR)","paramValue":"3.25","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.55","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0024","paramType":"Odds Ratio (OR)","paramValue":"2.51","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.00","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0115","paramType":"Odds Ratio (OR)","paramValue":"2.18","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"ciLowerLimit":"0.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.96","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6281","paramType":"Odds Ratio (OR)","paramValue":"0.70","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.62","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5103","paramType":"Odds Ratio (OR)","paramValue":"0.61","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.90","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7733","paramType":"Unadjusted Odds Ratio","paramValue":"1.15","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.81","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8370","paramType":"Odds Ratio (OR)","paramValue":"1.10","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.10","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1980","paramType":"Odds Ratio (OR)","paramValue":"1.75","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.21","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5391","paramType":"Odds Ratio (OR)","paramValue":"1.32","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.53","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0224","paramType":"Odds Ratio (OR)","paramValue":"1.97","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.77","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy, chronic pancreatitis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1815","paramType":"Odds Ratio (OR)","paramValue":"1.51","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2135"},{"groupId":"OG001","value":"20296"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"28"}]}],"title":"Tertile 1 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"27"}]}],"title":"Tertile 2 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"31"}]}],"title":"Tertile 3 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2120"},{"groupId":"OG001","value":"20222"}]}],"title":"Never (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"53"}]}],"title":"Tertile 1 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"43"}]}],"title":"Tertile 2 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"64"}]}],"title":"Tertile 3 (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2155"},{"groupId":"OG001","value":"20382"}],"units":"Participants"}],"description":"Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).","groups":[{"description":"Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident Pancreatic Cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident Pancreatic Cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.","title":"Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","type":"PRIMARY","unitOfMeasure":"participants"}